RAGE-Mediated Signalling in Gynaecological Disorders: Review of Molecular Mechanisms and Therapeutic Perspectives.

BACKGROUND

The receptor for advanced glycation end-products (RAGE) is a unique multi-ligand member of the immunoglobulin superfamily that exists in both membrane-bound and soluble forms. Under physiological conditions, RAGE expression is low in most tissues; however, it is markedly upregulated in response to tissue injury, inflammation or metabolic stress. Ligand-induced activation of RAGE initiates complex intracellular signalling cascades that regulate inflammation, extracellular matrix remodelling, cell proliferation, survival and migration.

METHODS

While the contribution of RAGE to diabetes and chronic inflammatory diseases is well established, its role in gynaecological disorders remains insufficiently characterized.

RESULTS

This comprehensive review summarizes current evidence on the involvement of RAGE in the pathogenesis of benign gynaecological disorders, such as endometriosis and polycystic ovary syndrome (PCOS), pregnancy-related complications and malignant neoplasms of the female reproductive tract.

CONCLUSIONS

It also discusses emerging therapeutic strategies aimed at targeting the RAGE pathway, highlighting their potential translational relevance in gynaecological practice.